Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL1243718

Nc1cccc(Nc2nccc(-c3cccc4c3oc3ccccc34)n2)c1.O=C(O)C(F)(F)F

nearest known ligand 0.47

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 3/20 0.47
BCR P11274 3/20 0.47
SRC P12931 3/20 0.47
EGFR P00533 2/20 0.47
PRKACA P17612 2/20 0.47
PRKACG P22612 2/20 0.47
PRKACB P22694 2/20 0.47
CAMK2D Q13557 2/20 0.44
CDK5 Q00535 1/20 0.43
CDK2 P24941 2/20 0.42
CDK4 P11802 1/20 0.42
SYK P43405 3/20 0.42
MAPK8 P45983 2/20 0.41
PIK3CG P48736 2/20 0.41
GSK3B P49841 2/20 0.41
CAMKK2 Q96RR4 2/20 0.41
CCNB2 O95067 2/20 0.41
CDK1 P06493 2/20 0.41
CCNB1 P14635 2/20 0.41
CCNB3 Q8WWL7 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL1244577 0.83 ALDH1A1 (0.40) ABL1BCREGFRCDK5CDK2
Trifluoroacetic Acid SCHEMBL1244880 0.79 AURKA (0.41) ABL1BCRSRCEGFRCDK2
Trifluoroacetic Acid SCHEMBL1242168 0.75 PIP4K2C (0.45) EGFRCCNT1CDK9
Trifluoroacetic Acid SCHEMBL1243690 0.75 CYP1A2 (0.41) ABL1BCRCCNT1CDK9
SCHEMBL25337558 0.73 ABL1 (0.63) ABL1BCRSRCEGFRPRKACA
SCHEMBL31118904 0.73 ABL1 (0.63) ABL1BCRSRCEGFRPRKACA
Trifluoroacetic Acid SCHEMBL1244552 0.72 PTGS1 (0.43) ABL1BCREGFRCCNT1CDK9
Trifluoroacetic Acid SCHEMBL1242021 0.72 PIP4K2C (0.49) ABL1BCREGFRCCNT1CDK9
SCHEMBL1242170 0.71 ABL1 (0.36) ABL1BCREGFRCDK5CDK2
SCHEMBL1241964 0.71 ABL1 (0.40) ABL1BCRSRCEGFRCDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7879853-B2 tyrosisne kinase inhibitors such as N-[4-(6-Dibenzofuran-4-yl-pyrimidin-4-ylamino)-phenyl]-4-morpholin-4-yl-benzamide, used as anticasrcinogenic or antoproliferative agents, especially in the treatment of breast cancer BAYER SCHERING PHARMA AG (DE) 2011-02-01 US disclosed
US-20070208034-A1 4,6-disubstituted pyrimidines and their use as protein kinase inhibitors ATLANTA PHARMA AG (DE) 2007-09-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070208034-A1 4,6-disubstituted pyrimidines and their use as protein kinase inhibitors CDK2, DCK, DTYMK ABL1 55/4885BCR 844/4885SRC 406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.